[go: up one dir, main page]

TR201005325A2 - Pharmaceutical formulations containing atorvastatin and aspirin - Google Patents

Pharmaceutical formulations containing atorvastatin and aspirin

Info

Publication number
TR201005325A2
TR201005325A2 TR2010/05325A TR201005325A TR201005325A2 TR 201005325 A2 TR201005325 A2 TR 201005325A2 TR 2010/05325 A TR2010/05325 A TR 2010/05325A TR 201005325 A TR201005325 A TR 201005325A TR 201005325 A2 TR201005325 A2 TR 201005325A2
Authority
TR
Turkey
Prior art keywords
aspirin
pharmaceutical formulations
formulations containing
containing atorvastatin
atorvastatin
Prior art date
Application number
TR2010/05325A
Other languages
Turkish (tr)
Inventor
Bi̇lgi̇ç Mahmut
Original Assignee
Bi̇lgi̇ç Mahmut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bi̇lgi̇ç Mahmut filed Critical Bi̇lgi̇ç Mahmut
Priority to TR2010/05325A priority Critical patent/TR201005325A2/en
Priority to PCT/TR2011/000161 priority patent/WO2012002919A1/en
Priority to PCT/TR2011/000163 priority patent/WO2012002920A1/en
Priority to EP11746335.6A priority patent/EP2588102A1/en
Priority to PCT/TR2011/000162 priority patent/WO2012011882A1/en
Priority to EP11764886.5A priority patent/EP2588103A1/en
Publication of TR201005325A2 publication Critical patent/TR201005325A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Mevcut buluş, kardiyovasküler hastalıkların tedavisi ve önlenmesinde kullanılmak üzere aspirin ve atorvastatin ve/veya bunların farmasötik açıdan kabul edilebilir tuzları, hidratları, enantiomerleri, rasematları, organik tuzları, inorganik tuzları, esterleri, polimorfları, kristal formları ve amorf formlarını ve/veya bunlara ait kombinasyonlarını içeren farmasötik bileşimlere ilişkindir.The present invention includes aspirin and atorvastatin and / or their pharmaceutically acceptable salts, hydrates, enantiomers, racemates, organic salts, inorganic salts, esters, polymorphs, crystal forms and amorphous forms and / or combinations thereof for use in the treatment and prevention of cardiovascular diseases. relates to pharmaceutical compositions containing

TR2010/05325A 2010-06-30 2010-06-30 Pharmaceutical formulations containing atorvastatin and aspirin TR201005325A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
TR2010/05325A TR201005325A2 (en) 2010-06-30 2010-06-30 Pharmaceutical formulations containing atorvastatin and aspirin
PCT/TR2011/000161 WO2012002919A1 (en) 2010-06-30 2011-06-29 Pharmaceutical formulations comprising atorvastatin and aspirin
PCT/TR2011/000163 WO2012002920A1 (en) 2010-06-30 2011-06-29 New dosage forms for treatment of cardiovascular diseases
EP11746335.6A EP2588102A1 (en) 2010-06-30 2011-06-29 New dosage forms for treatment of cardiovascular diseases
PCT/TR2011/000162 WO2012011882A1 (en) 2010-06-30 2011-06-29 A combination of atorvastatin and aspirin to be used in the treatment of cardiovascular diseases
EP11764886.5A EP2588103A1 (en) 2010-06-30 2011-06-29 A combination of atorvastatin and aspirin to be used in the treatment of cardiovascular diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TR2010/05325A TR201005325A2 (en) 2010-06-30 2010-06-30 Pharmaceutical formulations containing atorvastatin and aspirin

Publications (1)

Publication Number Publication Date
TR201005325A2 true TR201005325A2 (en) 2012-01-23

Family

ID=44487203

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2010/05325A TR201005325A2 (en) 2010-06-30 2010-06-30 Pharmaceutical formulations containing atorvastatin and aspirin

Country Status (3)

Country Link
EP (2) EP2588103A1 (en)
TR (1) TR201005325A2 (en)
WO (3) WO2012002920A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2844235A1 (en) * 2012-04-13 2015-03-11 Banner Pharmacaps, Inc. Soft elastic capsules containing tablets and liquid or semisolid fills and methods for their manufacture
KR101378973B1 (en) * 2012-04-13 2014-03-28 한미약품 주식회사 Hard capsule complex formulations comprising a multi-dose unit tablet of a near-spherical form and method for preparing the same
ES2524645B1 (en) * 2013-06-06 2015-12-02 Ferrer Internacional, S.A. Oral formulation for the treatment of cardiovascular diseases
RU2536275C1 (en) * 2013-08-06 2014-12-20 Строяковский Валентин Меерович Antihypoxic and hypolipidemic pharmaceutical agent improving coronary and cerebral blood flow
JP2018536710A (en) * 2015-11-06 2018-12-13 ジェンファイア・セラピューティクス・インコーポレイテッドＧｅｍｐｈｉｒｅ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． Treatment of mixed dyslipidemia
IL269884B2 (en) 2017-04-18 2023-09-01 Gemphire Therapeutics Inc Gemcabene, pharmaceutically acceptable salts thereof, compositions thereof and methods of use therefor
TW201906599A (en) * 2017-05-11 2019-02-16 美商珍費爾醫療公司 Gikabin composition and method of use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6235311B1 (en) * 1998-03-18 2001-05-22 Bristol-Myers Squibb Company Pharmaceutical composition containing a combination of a statin and aspirin and method
US6669955B2 (en) 2001-08-28 2003-12-30 Longwood Pharmaceutical Research, Inc. Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
US20040115265A1 (en) 2002-12-11 2004-06-17 Loutfy Benkerrour Multilayered tablet containing pravastatin and aspirin and method
WO2004080488A2 (en) * 2003-03-10 2004-09-23 Bayer Healthcare Ag Combined preparations of acetyl salicylic acid with an hmg-coa reductase inhibitor
MXPA05013147A (en) * 2003-06-06 2006-03-17 Takeda Pharmaceutical Solid pharmaceutical preparation.
EP1784193A4 (en) * 2004-06-28 2009-09-23 Smith Howard J & Ass Pty Ltd Composition and method for treatment and prevention of atherosclerosis
US20120015032A1 (en) * 2007-08-13 2012-01-19 Hanall Pharmaceutical Company, Ltd. Combination preparation comprising inhibitor of hmg-coa reductase and aspirin and method for manufacturing the same
CN101980701A (en) * 2008-03-28 2011-02-23 菲尔若国际公司 Capsule for the prevention of cardiovascular diseases
AU2010212580B2 (en) * 2009-02-11 2015-11-12 Cadila Pharmaceuticals Ltd. Stable pharmaceutical composition for atherosclerosis
KR101193493B1 (en) * 2010-02-02 2012-10-22 한미사이언스 주식회사 Composite formulation comprising aspirin coated with barrier containing water-insoluble additive and HMG-CoA reductase inhibitor

Also Published As

Publication number Publication date
EP2588103A1 (en) 2013-05-08
EP2588102A1 (en) 2013-05-08
WO2012002920A1 (en) 2012-01-05
WO2012002919A1 (en) 2012-01-05
WO2012011882A1 (en) 2012-01-26

Similar Documents

Publication Publication Date Title
WO2014028600A3 (en) 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
TN2012000465A1 (en) Derivatives of 1-amino-2-cyclopropylethylboronic acid
PE20121617A1 (en) OXAZINE DERIVATIVES AS BACE INHIBITORS
WO2014028591A3 (en) N-ALKYLATED INDOLE AND INDAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
EA201170434A1 (en) MACROCYCLIC INHIBITORS OF HYPATITIS C SERINE PROTEASIS
BR112012007747A2 (en) HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS, THEIR PHARMACEUTICAL COMPOSITION AND THEIR USES
IN2014MN02598A (en)
EA201300669A1 (en) SUBSTITUTED 1-BENZYL CYCLOALKYL CARBONIC ACIDS AND THEIR APPLICATION
AU2012214029A8 (en) Rorgammat inhibitors
EP2415763A4 (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF GLAUCOMA
IL224544B (en) Compound useful for the treatment of nonsense-mutation-mediated diseases and pharmaceutical composition comprising said compound
PH12013501800A1 (en) Tricyclic gyrase inhibitors
WO2011093826A3 (en) Effervescent formulations comprising cefaclor and clavulanic acid as active agents
EA201500365A1 (en) COMBINATION OF REGORAPHENIBE AND ACETYLSALICYLIC ACID TO CURE CANCER
TR201005325A2 (en) Pharmaceutical formulations containing atorvastatin and aspirin
TN2015000084A1 (en) NEW BICYCLIC PYRIDINONES
IN2014CN03597A (en)
EA201170356A1 (en) POLYMORPHIC AND AMORPHOUS FORMS OF LACOSAMIDE AND AMORPHOUS COMPOSITIONS
MY167898A (en) Co-crystals and salts of ccr3-inhibitors
EA201300034A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING IMATINIB OR ITS PHARMACEUTICALLY ACCEPTABLE SALT, AND WAYS TO OBTAIN THEM
EE201300004A (en) A combined pharmaceutical composition for the treatment of diseases or conditions of the cardiovascular system
CU24163B1 (en) TYPICAL OPHTHALMOLOGICAL PHARMACEUTICAL COMPOSITION CONTAINING REGORAFENIB
IT1397838B1 (en) COMPOSITION FOR TREATMENT OF PLANTS
PH12015502706A1 (en) Oral formulation for the treatment of cardiovascular diseases
HK1216721A1 (en) Uses and methods for the treatment of liver diseases or conditions